Clinical Trial Update: Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial exploring dalpiciclib in combination with exemestane, trastuzumab, and pyrotinib for early triple-positive breast cancer (ER+, HER2+).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Exemestane (Exemestane)
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Breast Cancer, Estrogen Receptor Positive Tumor | Phase 2 | Status: UNKNOWN